Taiwan’s Medigen COVID vaccine enters WHO data analysis trial stage

14-May-2022 Intellasia | TaiwanNews | 5:02 AM Print This Post

Medigen Vaccine Biologics Corp. (MVC), makers of the Medigen COVID vaccine (MVC-COV1901), announced on Thursday (May 13) that Phase 3 clinical trials have entered the data analysis stage.

MVC announced nearly all participants in clinical trials for Medigen, a candidate included in the WHO’s Solidarity Trial Vaccines (STV), have completed their two-dose regimen of either placebo or vaccine. The individually randomised, controlled Phase 3 clinical trials include 18,000 subjects in Colombia, Mali, and the Philippines.

The next stage is for independent statisticians to analyse the data and present their findings to a panel of experts in the STV steering committee. Once the analysis of interim data has been completed, the results will be released to the scientific community and the public for review.

Charles Chen, vice chair & CEO of MVC SAID “It has been an honor to have our vaccine evaluated in the Solidarity Trial Vaccines.” Chen thanked participants for providing data on the efficacy of vaccines “during Delta, Omicron and other variants that may arise during the trial.”

Provided the results of the trial are good and comply with regulations, Chen pledged the firm will make Medigen available to the public “at the earliest possible opportunity in an equitable and fair manner.” Medigen is currently widely available in Taiwan for first, second, and booster shots.



Category: Taiwan

Print This Post

Leave a Reply

You must be logged in to post a comment.